by Stephen Manobiano | Jul 1, 2026 | Automation, business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, news, Sales
Labs are getting smaller, more automated, and more distributed. Instruments are shrinking and handling more of the manual work themselves. Research hubs outside the traditional life science centers are standing up modular, flexible labs instead of building large...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Biomarker-guided drug development is now structural, not a passing trend; pharma and biotech companies rely on PD biomarkers to select doses, prove mechanism of action, and stratify patients across oncology, immunology, neurology, and rare disease. If you provide...
by Stephen Manobiano | Jun 30, 2026 | Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Genome editing is moving from a research tool into therapeutic development pipelines, and that shift is creating real, recurring demand for guide RNAs, delivery reagents, and validation kits. It’s also creating a commercial trap for reagent companies that don’t...
by Stephen Manobiano | Jun 30, 2026 | AI, Commercialization, Marketing, news, Sales
Every instrument vendor, every kit company, and every informatics platform now claims to be “AI-powered.” Which means the phrase has stopped doing any commercial work for you. Technical buyers have heard it enough times that it now triggers skepticism instead of...
by Stephen Manobiano | Jun 30, 2026 | Commercialization, Marketing, news, Sales
Cell biology is the largest single technology segment in the life science tools market, and “cell biology” is exactly the kind of label that flattens two very different sales motions into one generic pitch. Single-cell sequencing resolves heterogeneity inside a...
by Stephen Manobiano | Jun 18, 2026 | Commercialization, Fractional, news
I’ve spent the last several months at life science conferences, dinners, and networking events, talking to founders, CEOs, and investors. And I keep hearing the same thing, just in different rooms. Investors are stuck with Portfolios they can’t exit. Which...
